Literature DB >> 15700753

Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data.

M van der Kolk1, S J De Vlas, A Saul, M van de Vegte-Bolmer, W M Eling, R W Sauerwein, W Sauerwein.   

Abstract

Host responses to the transmittable stages of the malaria parasite may reduce transmission effectively. Transmission-reducing activity (TRA) of human serum can be determined as a percentage, using the Standard Membrane Feeding Assay (SMFA). This laboratory assay was evaluated using the results of 121 experiments with malaria-endemic sera among which many repeated measurements were obtained. The assay consists of the feeding of Anopheles stephensi mosquitoes with cultured Plasmodium falciparum gametocytes, mixed with human red blood cells, and control and experimental sera. The TRA of individual sera was determined by the comparison of oocyst densities between these sera. Bootstrap data on oocyst densities in individual mosquitoes in control feeds were used to construct confidence limits for TRA percentages of serum feeds. Low (<20%) and high TRA (>90%) values for individual sera were usually reproduced in a second experiment, whereas this was more difficult for values between 20% and 90%. The observed variability of TRA values is explained in part by the variability in oocyst density per mosquito. Oocyst densities in control feeds varied more between experiments than within experiments and showed a slight decline over the 3 years of experiments. Reproducibility of TRA of field sera was low (20%) between experiments, but much higher (61 %) within experiments. A minimum of 35 oocysts per mosquito in control feeds gave optimal reproducibility (44%) between experiments. We recommend that (1) sera are compared within an experiment, or (2) assays are only analysed where controls have at least 35 oocysts per mosquito. The SMFA is under the recommended conditions appropriate for the study of factors that may influence TRA, e.g. transmission blocking vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15700753     DOI: 10.1017/s0031182004006067

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  43 in total

Review 1.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 2.  Phenotypic Screens in Antimalarial Drug Discovery.

Authors:  Marisa L Hovlid; Elizabeth A Winzeler
Journal:  Trends Parasitol       Date:  2016-05-27

3.  The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species.

Authors:  Lediya Cheru; Yimin Wu; Ababacar Diouf; Samuel E Moretz; Olga V Muratova; Guanhong Song; Michael P Fay; Louis H Miller; Carole A Long; Kazutoyo Miura
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 4.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

5.  Optimizing Direct Membrane and Direct Skin Feeding Assays for Plasmodium falciparum Transmission-Blocking Vaccine Trials in Bancoumana, Mali.

Authors:  Mamadou B Coulibaly; Erin E Gabriel; Youssouf Sinaba; Daman Sylla; Adama Sacko; Lakamy Sylla; Boubacar Coulibaly; Jen C C Hume; Ibrahima Baber; Mahamadoun H Assadou; Issaka Sagara; Yimin Wu; Sara A Healy; Ogobara Doumbo; Sekou F Traore; Patrick E Duffy
Journal:  Am J Trop Med Hyg       Date:  2017-07-19       Impact factor: 2.345

6.  The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector.

Authors:  J C van Pelt-Koops; H E Pett; W Graumans; M van der Vegte-Bolmer; G J van Gemert; M Rottmann; B K S Yeung; T T Diagana; R W Sauerwein
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

7.  A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum.

Authors:  Christine E Farrance; Amy Rhee; R Mark Jones; Konstantin Musiychuk; Moneim Shamloul; Satish Sharma; Vadim Mett; Jessica A Chichester; Stephen J Streatfield; Will Roeffen; Marga van de Vegte-Bolmer; Robert W Sauerwein; Takafumi Tsuboi; Olga V Muratova; Yimin Wu; Vidadi Yusibov
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

Review 8.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

9.  The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48/45 in a low endemic area in Tanzania.

Authors:  Teun Bousema; Will Roeffen; Hinta Meijerink; Harry Mwerinde; Steve Mwakalinga; Geert-Jan van Gemert; Marga van de Vegte-Bolmer; Frank Mosha; Geoffrey Targett; Eleanor M Riley; Robert Sauerwein; Chris Drakeley
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

10.  Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice.

Authors:  Nikolay S Outchkourov; Will Roeffen; Anita Kaan; Josephine Jansen; Adrian Luty; Danielle Schuiffel; Geert Jan van Gemert; Marga van de Vegte-Bolmer; Robert W Sauerwein; Hendrik G Stunnenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.